Shandong Public Health Clinical Center
2 clinical trials · Sponsor
◉ Watch Shandong Public Health Clinical Center
| Record | Firm | Date |
|---|---|---|
| Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC (NCT06709859) | Shandong Public Health Clinical Center | 2025-05-01 |
| IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer (NCT05411757) | Shandong Public Health Clinical Center | 2022-06-30 |
Track Shandong Public Health Clinical Center automatically
Every clearance here is in the API, with alerts when new ones post.